A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
Status:
Recruiting
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when
administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants
who require red blood cell transfusions.